Abstract
<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Negre headshot sq.jpg" data-image="1"></div><div class="author-det"> <b>Olivier Negre, PhD </b>developed his expertise in preclinical research, bioassays, and drug development through more than 20 years of experience in biotherapies. After working on recombinant vaccines with Bioprotein Technologies, he joined bluebird bio (formerly Genetix Pharmaceuticals) and contributed for 15 years to the development of the first approved gene therapy for beta-thalassemia (ZyntegloTM). From preclinical studies to marketing authorization, he served as Senior Scientist/Team Leader in France and Director translational Research in the USA. He is currently, co-founder and Partner at Biotherapy Partners, acting Chief Development Officer of a biotech company, a participant in HEC Challenge+ program, board member of the French Society of Gene and Cell Therapy, expert of the Cure Sickle Cell initiative (NIH) and active member of the think-tank Gene and Cell Therapy Institute (G&CTI). Olivier graduated from ENSTBB engineering school and earned a PhD in cell and molecular biology from Paris Diderot University. He contributed to several patents and scientific publications in the field of gene and cell therapy (e.g. <i>Nature </i>2010, <i>Blood</i> 2011, <i>Stem Cells</i> 2013, <i>Current Gene Therapy</i> 2015, <i>Human Gene Therapy </i>2016, <i>The New England Journal of Medicine </i>2017, <i>The New England Journal of Medicine</i> 2018, <i>Science Translational</i> 2019, <i>Molecular Therapy Methods & Clin. Dev.</i> 2020, <i>BioDrugs </i>2020, <i>T</i><i>he New England Journal of Medicine </i>2021). </div></div></div>
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
